USPTO grants patent for LexisNexis PatentSight

Posted by LexisNexis PatentSight team on Sep 9, 2019 2:56:14 PM

PatentSight is proud to announce that our patent analytics software is now a patent protected Intellectual Property. In August, 2019, the USPTO officially granted Nils Omland, our founder and CEO, with a patent for the PatentSight Business Intelligence software solution. Back in 2018, when LexisNexis® acquired PatentSight, this patent was still undergoing review. The granting of this patent makes our SaaS offering, officially, one of its kind.

Read More

Tags: Technology, Science, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, patent


Innovation in merger analysis - How the EU Commission evaluated the case of Bayer-Monsanto

Posted by Carsten Guderian and Nabu Xavier on Sep 4, 2019 3:03:21 PM

In September 2016, the German drugs and chemicals group Bayer announced its intention to acquire the multinational Monsanto, known for its Roundup herbicide and GMOs. This merger would produce the world’s most powerful company in the seed and pesticide industry. On 21 March 2018 the EU commission released a Press Release announcing their approval of the acquisition of Monsanto by Bayer. The merger was approved on the conditional divestiture of an extensive remedy package, which addresses the parties' overlaps in seeds, pesticides and digital agriculture. It is for determining such inconspicuous aspects of a merger, like technology overlap, that the EU commission relied on the LexisNexis® PatentSight® database and our award-winning Business Intelligence software solution.

Read More

Tags: Technology, Science, Mergers and Acquisitions, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, M&A, Merger Evaluation, EU Commission, Competition Control


China in Rare Earth Elements - top supplier, major patent developer, yet portfolio strength still a concern

Posted by William Mansfield on Sep 4, 2019 10:33:56 AM

From recent news reports it became clear that China accounts for almost 90% of the world’s production and supply of the so-called Rare Earth Elements (REE). These are a group of 17 elements that are not commonly found in the earth's surface. For e.g. Scandium, one of the rare earth elements, is heavily used in manufacturing parts for the aerospace industry. Similarly, these elements have varied and extremely specific uses, for which, at least for the time-being, no viable substitutes can be sourced. We used our excellent patent database and scientifically proven metrics to analyze the current situation around rare earth elements from a patent quality point of view to identify possible opportunities and threats in this business.

Read More

Tags: Technology, Science, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, Rare earth metals, China, USA, rare earth elements


10 Charts That Will Change Your Perspective Of Amazon's Patent Growth

Posted by Louis Columbus - Guest Contributor on Aug 15, 2019 4:19:29 PM


跳转到简体中文 (jump to Simplified Chinese):

10 张图表,以不同角度看亚马逊的专利增长趋势

 

  • Since 2010 Amazon has grown its patent portfolio from less than 1,000 active patents in 2010 to nearly 10,000 in 2019, a ten-fold increase in less than a decade.

  • Amazon heavily cites Microsoft, IBM, and Alphabet, with 39%, 32% and 28% of Amazon’s total Patent Asset Index

  • Amazon’s patent portfolio is dominated by Cloud Computing, with the majority of the patents contributing to AWS’ current and future services roadmap. AWS achieved 41% year-over-year revenue growth in the latest fiscal quarter, reaching $7.6B in revenue.

Read More

Tags: Technology, IP Data Quality, Patent Analysis, Patent Valuation, Patent Asset Index, IP Benchmarking, Benchmarking, Deep-dive, Future, trend scouting, big data, solutions provider


A case study of Palantir: Using advanced patent analytics to aid investment decisions

Posted by Ninja Laufmann on Apr 29, 2019 2:04:15 PM

In a newly released whitepaper PatentSight takes a deep dive into the portfolio of Palantir – one of Silicon Valley’s most secretive companies – to demonstrate how advanced patent analytics can be used to provide critical insights for investment decisions.

Read More

Tags: Technology, Patent Analysis, Patent Valuation, Innovation, Patent Asset Index, IPO Analyses


Israeli Innovation Leader - A patent analysis

Posted by William Mansfield on Mar 12, 2019 9:32:59 AM

Recently, we applied the PatentSight Patent Asset Index methodology to gain a new insight into which of Israel’s research bodies are leading in innovation. The index assesses the strength of an organization’s patent portfolio in terms of quality of patents held measured by TechnologyRelevance™ and Market Coverage ™. So, what did we find?

 

Read More

Tags: Science, Patent Analysis, Innovation, Patent Asset Index


Samsung’s runaway lead in foldable displays by Patent Asset Index™

Posted by William Mansfield on Mar 4, 2019 10:54:00 AM

End of February 2019 Samsung revealed its long rumored smart phone with a foldable display, the first of its kind to have an official release date. A number of players have been rumored to be working on such devices, however Samsung’s combination of in-house smartphone and display technologies may have led to it being first to market.

A closer look at the innovation landscape and the qualitative strength of the patent portfolios in the field of foldable smartphone technology shows the enormous lead Samsung has and the areas in which Apple has to catch up.

Read More

Tags: Technology, Patent Analysis, Innovation, Patent Asset Index


Patent analysis reveals opportunities and concerns around the Bristol-Myers Squibb/Celgene merger

Posted by William Mansfield on Feb 25, 2019 4:46:01 PM

In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.

The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.

Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.

Read More

Tags: Science, Mergers and Acquisitions, Patent Analysis, Patent Asset Index


Tesla to buy Maxwell Technologies: an important technological edge in the battery market for electric cars

Posted by William Mansfield on Feb 7, 2019 9:47:00 AM

With the acquisition of Maxwell Technologies, Tesla expands its patent portfolio and includes technologies that may lead to a major advantage in the future technology of efficient batteries for electric cars. The company is a specialist in the field of energy storage. For Tesla this can mean a leap forward in the highly competitive field of battery technology for electric cars. A closer look at this acquisition scenario shows us in which technology areas Maxwell can significantly complement Tesla's patent portfolio.

Read More

Tags: Technology, Mergers and Acquisitions, Patent Analysis, Innovation, Patent Asset Index


Roche up, Pfizer out - The Patent Asset Index™ for Alzheimer’s and Parkinson’s patents

Posted by Benjamin Hann on Oct 16, 2018 8:33:56 AM

 

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

Read More

Tags: Patent Analysis, Patent Valuation, Patent Asset Index